Syncona's Anaveon to present first clinical data from ANV419 study

Syncona stated that Anaveon's presentation will reveal that as of the data cut-off date, 16 patients across seven dosing cohorts with different types of progressing cancer had received ANV419, with data showing the candidate was "very well-tolerated", with highly favourable safety data, robust and consistent pharmacodynamic effects, and excellent selectivity for inducing proliferation of relevant immune effector cells.

The FTSE 250-listed firm added that based on "the highly encouraging mechanistic data" from the Phase I/II programme, a Phase II study of ANV419 had been initiated in multiple tumour types, including melanoma, to evaluate clinical efficacy in both monotherapy and combination settings.

Christoph Bucher, Anaveon's chief medical officer, said: "The safety and selectivity of ANV419 observed in the pre-clinical studies have fully translated in the data in this Phase I/II study. The long half-life of ANV419, we believe, has the potential to allow us to select the most appropriate dose level without incurring the side effects seen by other IL-2 therapies.

"The unique characteristics of ANV419 point to its potential as a transformational therapy for patients with cancer, both as monotherapy and in combination with other therapies."